Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
Lenalidomide improves PFS after 1st and 2nd line CLL therapy
Publish date:
December 14, 2016
AT ASH 2016
op@frontlinemedcom.com
Pages
« first
1
2
Recommended Reading
Ibrutinib at below standard dose may achieve good survival in CLL
MDedge Hematology and Oncology
Acalabrutinib shows efficacy as monotherapy in untreated CLL
MDedge Hematology and Oncology
Three-drug regimen boosts progression-free survival in patients with relapsed CLL and adverse prognostic features
MDedge Hematology and Oncology
CAR T-cell therapy eyed for CLL patients with residual disease
MDedge Hematology and Oncology
CLL: Genetic aberrations predict poor treatment response in elderly
MDedge Hematology and Oncology
Survival in CLL predicted by minimum residual disease
MDedge Hematology and Oncology
CD49d trumps novel recurrent mutations for predicting overall survival in CLL
MDedge Hematology and Oncology
Minimal residual disease status predicts 10-year survival in CLL
MDedge Hematology and Oncology
Targeted therapies predicted to blow out costs for CLL
MDedge Hematology and Oncology
Idelalisib held unlikely to become frontline therapy for CLL
MDedge Hematology and Oncology
CLL
Leukemia, Myelodysplasia, Transplantation
All Specialties
